Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
RESEARCH TOOLSreports
PTGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.22 - $48.89
Previous CloseN/A
Volume120.35K
Average Volume (3M)626.70K
Market Cap
$2.31B
Enterprise Value$2.32B
Total Cash (Recent Filing)$82.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)8.9
Beta0.39
Next Earnings
Apr 30, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding61,384,290
10 Day Avg. Volume807,365
30 Day Avg. Volume626,699
Standard Deviation0.28
R-Squared0.17
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.31
Price to Cash Flow (P/CF)-19.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda15.33
Forecast
1Y Price Target
$58.10Price Target Upside54.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRusfertide met the primary and all four key secondary endpoints in VERIFY study, confirming its blockbuster potential in the polycythemia vera market.
Commercial OpportunityAnalysts discussed the commercial opportunity with 155K diagnosed U.S. patients, estimating a $1-$2B opportunity based on rusfertide’s clinical profile and unmet need.
Bears Say
Safety ConcernsSafety details were sparse in the top line but PTGX did say there were no drug-related serious adverse events or increased risk of cancer vs. placebo, which gives comfort.
---
Ownership Overview
1.78% Insiders
16.13% Mutual Funds
0.17% Other Institutional Investors
53.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $24.22 and its highest was $48.89 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $2.31B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 57 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Feb 21, 2025. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.592.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 61,384,290 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of $1.98 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 0.676%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
---
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.10 (54.56% Upside)
$58.10 (54.56% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 81.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.52%
12-Months-Change
Fundamentals
Return on Equity
54.39%
Trailing 12-Months
Asset Growth
108.51%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
---
PTGX Stock 12 Month Forecast
Average Price Target
$58.10
▲(54.56% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Exelixis
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Enanta Pharmaceuticals
―
Best Analysts Covering PTGX
1 Year
1 Year Success Rate
18/20 ratings generated profit
1 Year Average Return
+66.36%
reiterated a buy rating yesterday
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +66.36% per trade.
---